| Recruiting | Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis NCT07146971 | Good Molecules, LLC | Phase 1 |
| Not Yet Recruiting | Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis NCT07162896 | Shalamar Institute of Health Sciences | Phase 3 |
| Not Yet Recruiting | Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica NCT07448363 | Caja Costarricense de Seguro Social | — |
| Enrolling By Invitation | A Pilot Study on the Efficacy of 2% Cholesterol Cream in Preventing Transepidermal Water Loss and Clinical Sym NCT07503197 | Institute of Dermatology, Thailand | N/A |
| Recruiting | A Phase 1 Study of GS101 Injection NCT07411755 | Jiangsu Genscend Biopharmaceutical Co., Ltd | Phase 1 |
| Recruiting | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 NCT07453602 | Arcutis Biotherapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema NCT07438509 | Jinnah Postgraduate Medical Centre | Phase 4 |
| Not Yet Recruiting | Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease NCT07455578 | Seismic Therapeutic AU Pty Ltd | Phase 1 |
| Not Yet Recruiting | A Phase III Study of GS101 Injection to Dupixent® NCT07386743 | Jiangsu Genscend Biopharmaceutical Co., Ltd | Phase 3 |
| Not Yet Recruiting | Exploratory Clinical Investigation on Neurosensory Responses Via EEG Headband in Adults With Mild to Moderate NCT07333300 | NovoBliss Research Pvt Ltd | N/A |
| Recruiting | Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis NCT07298395 | Enveda Therapeutics | Phase 2 |
| Recruiting | A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. NCT07230483 | Keymed Biosciences Co.Ltd | Phase 2 |
| Not Yet Recruiting | Moisturization and Skin Hydration Study NCT07270965 | University of British Columbia | N/A |
| Recruiting | A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and NCT07235384 | Zai Lab (Shanghai) Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults NCT07276620 | Xiangya Hospital of Central South University | N/A |
| Completed | Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild NCT07329101 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 |
| Not Yet Recruiting | A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermati NCT07175233 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis NCT07205081 | Attovia Therapeutics Inc | Phase 1 |
| Not Yet Recruiting | A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atop NCT07173478 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Col NCT07259343 | Universidad Autónoma de Aguascalientes | N/A |
| Completed | Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis NCT07336940 | Enveda Therapeutics | Phase 1 |
| Not Yet Recruiting | A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis NCT07184645 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis NCT07103174 | Shanghai Mabgeek Biotech.Co.Ltd | Phase 2 |
| Recruiting | SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495 | Leiden University Medical Center | — |
| Recruiting | The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis NCT06928246 | Daniel Kaplan | Phase 1 |
| Recruiting | A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis NCT07105488 | Bluefin Biomedicine, Inc. | Phase 2 |
| Recruiting | Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis NCT06982352 | LAPIX Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | Effectiveness of Psychodermatologic Educational Modules on Atopic Dermatitis Patient Outcomes NCT07009483 | University of Alberta | N/A |
| Active Not Recruiting | A Study for HSK44459 in Participants With Atopic Dermatitis NCT06996912 | Xizang Haisco Pharmaceutical Co., Ltd | Phase 2 |
| Completed | A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermat NCT06923228 | CAGE Bio Inc. | Phase 2 |
| Not Yet Recruiting | A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese A NCT06931990 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function NCT06943469 | Société des Produits Nestlé (SPN) | N/A |
| Active Not Recruiting | Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants NCT06920693 | Generate Biomedicines | Phase 1 |
| Recruiting | Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. NCT06855745 | Alphyn Biologics | Phase 2 |
| Recruiting | CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Derm NCT07204561 | Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse | N/A |
| Enrolling By Invitation | A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis. NCT07180511 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Phase 3 |
| Recruiting | Herbal Ointment in Treating Atopic Dermatitis Topically NCT06850311 | En Chu Kong Hospital | Phase 2 / Phase 3 |
| Completed | Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis NCT06723405 | Evommune, Inc. | Phase 2 |
| Completed | A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement NCT07066150 | Shanghai Chicmax Cosmetic Co., Ltd. | N/A |
| Active Not Recruiting | Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patient NCT06787586 | Attovia Therapeutics Inc | Phase 1 |
| Completed | Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of At NCT06810050 | CAGE Bio Inc. | Phase 2 |
| Completed | Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis NCT06631170 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Partic NCT06503536 | AbbVie | — |
| Completed | Comparison Between Topical N-acetyl Cysteine (NAC) in Cold Cream Versus Cold Cream in Mild and Moderate Atopic NCT07323719 | Cairo University | N/A |
| Completed | Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis NCT07113366 | Kaohsiung Veterans General Hospital. | Phase 1 |
| Completed | In-Use Tolerance Study Under Dermatological and Pediatric Controls of Sunscreen in Children With Atopic Dermat NCT07194408 | Pierre Fabre Dermo Cosmetique | — |
| Completed | In-Use Tolerance & Efficacy Study Under Dermatological Control of Sunscreen in Adults With Atopic Dermatitis S NCT07194421 | Pierre Fabre Dermo Cosmetique | — |
| Recruiting | Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis NCT07316465 | Universitair Ziekenhuis Brussel | N/A |
| Active Not Recruiting | Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adole NCT05959083 | AbbVie | — |
| Completed | A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis NCT07185282 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 |
| Completed | Study of LW402 in Moderate-to-Severe Atopic Dermatitis NCT07186387 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Phase 2 |
| Completed | Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis. NCT07301658 | i+Med S.Coop. | N/A |
| Completed | To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patient NCT05650320 | Otsuka Beijing Research Institute | Phase 3 |
| Completed | To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD NCT05667623 | Otsuka Beijing Research Institute | Phase 3 |
| Completed | Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis NCT05456529 | Incyte Corporation | Phase 3 |
| Completed | A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis NCT05372653 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children NCT06361992 | Catalysis SL | Phase 3 |
| Completed | MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis NCT07182864 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 / Phase 2 |
| Completed | A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korea NCT04541810 | AbbVie | — |
| Withdrawn | A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With M NCT04666675 | AbbVie | Phase 3 |
| Completed | A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects NCT04056130 | KoBioLabs | Phase 1 |
| Completed | Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administra NCT04173442 | Regeneron Pharmaceuticals | — |
| Terminated | Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis NCT03389893 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Completed | Targeted Microbiome Transplant in Atopic Dermatitis NCT03151148 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Atopic Dermatitis (AD) and Food Allergy NCT03168113 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema NCT02357940 | Johnson & Johnson Consumer Inc. (J&JCI) | N/A |
| Completed | Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) NCT01979016 | Regeneron Pharmaceuticals | Phase 2 |